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Background: This study investigated the incidence and patient- and treatment-related risk factors related to
pneumonia acquired during radiotherapy (PNRT) in head and neck cancer (HNC) patients.
Methods: Using the universal insurance claims data, 15,894 total HNC patients between 1998 and 2007 were
included in this analysis. PNRT was defined as the occurrence of pneumonia within 90 days of the commencement
of radiotherapy. Information also included some demographic characteristics, treatment-related factors, and
comorbidities. Appropriate statistical tests were performed to assess the difference between patients with and
those without PNRT. A logistic regression was used to estimate the odds ratio (OR) of PNRT among the variables
examined.
Results: In total, 772 patients (4.86%) were identified with PNRT as the case group, whereas 15,122 subjects of the
same cancer without PNRT formed the control group. Of patients with PNRT, 632 (81.9%) were hospitalized with a
mean length of stay of 25.9 days. Results from the multiple logistic regression showed that an older age and certain
comorbidities were associated with an increased risk of PNRT. Patients with cancer of the tongue, buccal mucosa,
oropharynx, and hypopharynx/larynx were at particularly higher risk (OR = 1.28, 1.28, 1.67, and 1.74, respectively).
Compared to radiotherapy alone, concurrent chemoradiotherapy had no effect on the PNRT. Patients in the PNRT
group had higher overall medical costs and length of stay.
Conclusion: The incidence of PNRT in HNC patients receiving radiotherapy was approximately 5%. Notably, an
older age, certain comorbidities, and certain specific tumor sites were associated with an increased risk.
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It was recently estimated that there are more than half
a million new cases of head and neck cancer (HNC)
diagnosed annually worldwide [1]. Over the past few
decades, radiotherapy (RT) or concurrent chemoradiothe-
rapy (CCRT) has become the standard of care for HNC
patients as definitive or adjuvant treatment. Previous
studies have reported HNC patients to be at a greater
risk of aspiration pneumonia on account of the severe dys-
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reproduction in any medium, provided the orfollowing RT [2-5], with 33-81% of HNC patients having
been reported to suffer aspiration pneumonia during RT
therapy [3,5-10].
In addition to being the most common cause of infec-
tious death among cancer patients [11], an episode of
pneumonia can severely impact the course of RT by
requiring treatment interruption or prolongation, thus
jeopardizing local control [12]. While However, to date no
population-based estimates of pneumonia incidence during
RT have been reported and there is a paucity of data
regarding the association between pneumonia and certain
factors such as demography, tumor site, and comorbidities.
Therefore, this study set out to estimate the incidence
of pneumonia acquired during RT (PNRT) and to explore
its risk factors in HNC patients. We utilized data sourced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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gram to perform a population-based analysis investigating
the associations between the occurrence of PNRT and vari-
ous demographic factors and co-morbidities. These results
will help establish a risk model and prioritize preventive
efforts for those at greatest risk.Day








Figure 1 Incidence* of pneumonia in head and neck cancer
patients. This figure presents the incidence of pneumonia beginning
with the initiation of radiotherapy. The thick line illustrates the incidence.Methods
Data source
The Taiwan Department of Health combined 13 insu-
rance systems into a universal National Health Insurance
program in March 1995. Approximately 99% of the
population has been covered by this system since 1999.
The National Health Research Institute (NHRI) pro-
duces computerized medical claims and selected sets of
healthcare data for administrative use and research, as
described in a large retrospective study [13,14]. We used
the NHRI data from 1998 to 2007, including all inpatient
and ambulatory care records for cancer care and a
registry of catastrophic illness patients, which also con-
tain basic demographic information of insured residents.
We used the International Classification of Disease, 9th
Revision, Clinical Modification (ICD-9-CM) to identify
the disease and retrieve information on diagnoses of
these patients. Because the NHRI database provided by
the official NHI program consists of totally de-identified,
encrypted, secondary data released to the public for re-
search purposes without personal or institutional identi-
fication or contact with the study patients, the study was
exempt from full review by the institutional review
board (IRB) of China Medical University Hospital.Study subjects
We selected 27,617 newly diagnosed patients with
HNCs, (ICD-9-CM 140~149) from the registry for
catastrophic illness patients between 1998 and 2007. All
patients were treated with RT (ICD-9-CM-OP 922 and
V580) after the diagnosis. Locations of the HNCs inclu-
ded the lips (ICD-9-CM 140), tongue (ICD-9-CM 141),
salivary glands (ICD-9-CM 142), gums (ICD-9-CM 143),
mouth floor (ICD-9-CM 144), buccal mucosa (ICD-9-
CM 145), oropharynx (ICD-9-CM 146), nasopharynx
(ICD-9-CM 147), hypopharynx (ICD-9-CM 148), and
unknown primary (ICD-9-CM 149).
The first date of RT was defined as the index date.
After excluding patients with pneumonia (ICD-9-CM
481~482 and 485~486) before the index date, those
younger than 20 years, and patients receiving chemo-
therapy before RT, 15,894 HNC patients were included
in this analysis. As depicted in Figure 1, HNC patients
were particularly at risk of pneumonia within 90 days from
the index date. Thereafter, the rate of the pneumonia-free
proportion stabilized. Thus, the study group was definedas those with the occurrence of PNRT within 90 days after
the index date.
Patient information retrieval also included selected
sociodemographic characteristics, treatment-related factors,
and comorbidities, including age (20–49, 50–64, and ≥ 65
years), gender, level of hospital (medical center, regional
hospital, or district hospital), neck lymph node dissec-
tion (ICD-9-CM-OP 403~405), a gastrostomy (ICD-9-
CM-OP 430, 431, 463, 463.2, and 463.9), chemotherapy
(ICD-9-CM-OP V581 and 992.5), dementia (ICD-9-CM
290 and 294), stroke (ICD-9-CM 430~438), gastroeso-
phageal reflux disease (GERD, ICD-9-CM 530.11, 530.81,
and 787.1), and Parkinson’s disease (PD; ICD-9-CM 332).
All comorbidities were identified before the diagnosis of
HNCs. CCRT patients were recognized when chemother-
apy was administrated during the RT course. Gastrostomy
was adjusted for if performed prior to the index date.
Statistical analysis
We used SAS software version 9.1 (SAS Institute, Cary,
NC) for the analysis. Chi-squared and Fisher’s exact tests
were performed to test for differences in sociodemogra-
phic characteristics and medical records between HNC
patients with and without pneumonia. A t-test was
utilized to examine differences in age and medical costs
between groups. A logistic regression was used to
estimate the odds risk (OR) of having PNRT among
associated factors, after controlling for certain variables.
A two-sided p of < 0.05 was considered statistically
significant.
Results
Among 15,894 HNC patients, 772 patients (4.86%) were
identified as having PNRT and were labeled the case
group, with 15,122 HNC patients without PNRT as the
control group. Table 1 summarizes the characteristics of
the two groups. Compared to the control group, there
Table 1 Socio-demographic data between head and neck
cancer patients with and without pneumonia acquired
during radiotherapy (PNRT)
PNRT
No N=15,122 Yes N=772
Variable n % n % p value
Men 12,629 83.5 689 89.3 < 0.0001
Age (years) < 0.0001
< 50 7635 50.5 238 30.8
50~64 5320 35.2 287 37.2
≥ 65 2167 14.3 247 32.0
Mean (SD) 51.2 (12.1) 58.0 (13.2) < 0.0001
Hospital level 0.001
Medical center 9799 64.8 523 67.8
Regional hospital 3475 23.0 189 24.5
District hospital / clinic 1848 12.2 60 7.8
Treatment
Neck lymph node dissection 3066 20.3 123 15.9 0.003
Gastrostomy 182 1.2 28 3.6 < 0.0001
Concurrent chemotherapy 6881 45.5 354 45.9 0.85
Comorbidity
Dementia 41 0.3 4 0.5 0.28†
Stroke 418 2.8 46 6.0 <0.0001
Parkinson’s disease 19 0.1 5 0.7 0.005†
GERD 664 4.4 51 6.6 0.004
† Fisher’s exact test.
GERD gastroesophageal reflux disease.
Table 2 Univariate and multivariate logistic regression
estimating odds ratio (OR) of developing pneumonia
acquired during radiotherapy (PNRT) among variables
Variable UnivariateOR (95% CI)
Multivariate
OR (95% CI)
Male (vs. Female) 1.64 (1.30~2.07) 1.77 (1.40~2.24)
Age (vs. < 50 years)
50~64 1.73 (1.45~2.06) 1.67 (1.40~2.00)
≥ 65 3.66 (3.04~4.40) 3.54 (2.93~4.28)
Hospital level (vs. District hospital/clinic)
Medical center 1.64 (1.25~2.16) 1.69 (1.29~2.23)
Regional
hospital
1.68 (1.25~2.25) 1.68 (1.25~2.26)
Treatment (vs. no)
Neck dissection 0.75 (0.61~0.91) 0.77 (0.63~0.94)
Gastrostomy 3.09 (2.06~4.63) 2.94 (1.94~4.44)
Comorbidity (vs. no)
Stroke 2.23 (1.63~3.05) 1.35 (0.98~1.87)
Parkinson’s
disease
5.18 (1.93~13.9) 3.01 (1.09~8.30)
GERD 1.54 (1.15~2.07) 1.48 (1.09~1.99)
Cancer site
Lip 0.63 (0.23–1.71) 0.63 (0.23–1.73)
Tongue 1.13 (0.91–1.40) 1.28 (1.02–1.61)
Salivary gland 0.74 (0.30–1.81) 0.57 (0.23–1.40)
Gum 0.85 (0.53–1.36) 0.70 (0.43–1.14)
Mouth floor 1.67 (0.94–2.95) 1.75 (0.98–3.13)
Buccal mucosa 1.31 (1.11–1.55) 1.28 (1.07–1.53)
Oropharynx 1.90 (1.54–2.36) 1.67 (1.36–2.10)
Nasopharynx 0.46 (0.39–0.53) 0.46 (0.39–0.54)
Hypopharynx 2.33 (1.86–2.93) 1.74 (1.37–2.21)
Unknown 1.21 (0.65–2.23) 1.10 (0.59–2.04)
GERD gastroesophageal reflux disease.
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age (median age; 58.0 vs. 51.2 years), treated at medical
centers, received pretreatment gastrostomy, and asso-
ciations with certain comorbidities (including stroke,
GERD, and PD). Nevertheless, a lower proportion of
subjects in the study group were treated with neck
lymph node dissection before RT. As shown in Table 2,
the logistic regression showed that an older age, treat-
ment center, a gastrostomy, and comorbidities were
associated with an increased risk of PNRT, whereas
those receiving neck lymph node dissections had a
lower risk. Patients with cancer of the tongue (Odds ra-
tio (OR)=1.28; 95% confidence interval (CI)=1.02~1.61),
buccal mucosa (OR=1.28, 95% CI=1.07~1.53), oropha-
rynx (OR=1.67, 95% CI=1.36~2.10), and hypopharynx
(OR=1.74, 95% CI=1.37~2.21) were at greater risk of
PNRT after adjusting for age, gender, level of hospital,
treatment, and comorbidities. In particular, nasopha-
ryngeal cancer patients had a substantially lower risk of
PNRT.
Table 3 summarizes the ORs of PNRT among different
treatment combinations compared to RT alone. CCRT
was not associated with an increased risk of PNRT(OR = 1.12, 95% CI 0.95~1.32). When neck lymph node
dissection was performed before RT, there was a trend
toward a lower risk (OR = 0.75, 95% CI 0.58~0.98). In
contrast, neck lymph node dissection followed by CCRT
did not significantly decrease the risk of PNRT. To deter-
mine the cause of this disparity, further analysis investi-
gated sociodemographic differences between those with
and without lymph node dissection. The results showed
that there was a lower proportion of lymph node dis-
section in the older age group compared to the younger
age group (16.5% vs. 9.8% in patients aged ≥ 65 years,
p < 0.0001).
A cost analysis was carried out to estimate the impact
of PNRT on hospital resources spent, and results are
shown in Table 4. Based on calculations of the average
medical expenses within 90 days after the index date,
there was a significant difference between patients with
Table 3 Adjusted odds ratio (OR) of having pneumonia
acquired during radiotherapy (PNRT) among different
treatment modalities
Treatment n Cases OR* (95% CI)
RT alone 6397 336 1.00 (reference)
Neck lymph node dissection plus RT 1915 72 0.75 (0.58~0.98)
CCRT alone 5961 303 1.12 (0.95~1.32)
Neck lymph node dissection plus
CCRT
1274 51 0.88 (0.65~1.20)
*: After controlling for gender, age, level of hospital, stroke, gastroesophageal
reflux disease, and Parkinson’s disease.
CCRT concurrent chemoradiotherapy, RT radiotherapy.
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were hospitalized with a mean length of stay of 25.9 days.
Those with PNRT spent an additional US$11,612 (approxi-
mately US$188/day) on overall medical costs (p < 0.0001)
and had an extra 5 days for the LOS (p < 0.0001).
Discussion
In HNC patients, more-aggressive treatment might pro-
duce unintended consequences such as an increased risk
for pneumonia. To the best of our knowledge, this study
is the first population-based analysis incorporating de-
mographic, treatment-related factors, tumor sites, and
comorbidities to investigate the incidence of PNRT and
its risk factors. Our results demonstrate that HNC pa-
tients are at particularly high risk of pneumonia within
three months following the initiation of RT.
These findings highlight a challenge for radiation
oncologists as pneumonia has a negative effect on RT,
and often necessitates treatment interruption or pro-
longation, thus jeopardizing local control and raising the
risk of tumor repopulation [12]. Therefore it is the hope
of the authors that these results be used to help optimize
treatment outcomes.
Patients with some specific tumor sites were at a
particularly increased risk for pneumonia, which offers
further support for some underlying mechanisms and may
indicate the how clinical improvements may be directed.
This information is also useful to clinicians who may con-
sider increased surveillance on higher risk individuals.
After stratifying by cancer site, our data indicated that
patients with hypopharyngeal, oropharyngeal, tongue,Table 4 Medical costs* between groups with and without pne
No
Variable N Mean
Overall medical costs (US$) 15,122 9744.7
Average daily medical costs (US$) 15,122 119.8
Length of stay 8257 22.9
*: Cost calculated for each patient within 90 days from the start of radiotherapy.and buccal cancers were at a 1.28~1.74-fold higher risk
of developing PNRT. This is in line with previous studies
which have suggested HNC patients to be at a greater
risk of aspiration pneumonia on account of the severe
dysfunction of the tongue, larynx, and pharyngeal mus-
cles following RT [2-5,15]. For pharyngeal cancers, the
close proximity of the pharyngeal constrictors to the
tumor causes patients to be susceptible to dysphagia,
with dysphagia having been demonstrated to carry an
increased risk of aspiration [16].
These results also support those of our previous study
[17] in which we found maximal dysphagia score during
CCRT to be a prognostic factor in predicting early
termination of treatment. Thus, careful monitoring of
aspiration pneumonia is essential for patients in whom
dysphagia worsens during the RT/CCRT course.
We further feel that these data support the use of
novel RT techniques to spare the swallowing structures
in terms of avoiding aspiration pneumonia during RT
and preventing long-term complications [3,5,6,18,19].
Two studies have already been conducting indicating
that by sparing the pharyngeal constrictors the incidence
of severe dysphagia can be reduced during the RT course
[8,18].
The present study was also the first to identify patients
with tongue or buccal cancers to be at an increased risk of
developing PNRT. Because most patients with these
cancers are treated with wide excision and reconstruction,
one reason might be attributed to the fact that many
reconstruction procedures cannot entirely compensate for
swallowing dysfunction. As a result, some patients are still
susceptible to both dysphagia and aspiration during the
RT course.
Our results showed that patients pretreated with a
gastrostomy had an increased risk of PNRT, whereas RT
alone plus neck lymph node dissection lowered the
hazard. The former was probably due to a selection bias,
because those experiencing severe dysphagia are always
advised to have a feeding gastrostomy. The latter might
be attributed to a predisposition for an uneven age dis-
tribution between patients with or without neck node
dissection.
As several studies have pointed out that pneumonia has
become another major source of post-CCRT morbidity inumonia acquired during RT (PNRT) by t-test
PNRT
Yes
SD N Mean SD p value
4729.5 772 11,612.3 7520.5 < 0.0001
66.1 772 187.9 98.3 < 0.0001
29.6 693 27.6 26.0 < 0.0001
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to estimate the association between pneumonia and post-
CCRT. However, in contrast with one study performed by
Francis et al. utilizing SEER data to analyze dysphagia,
stricture, and pneumonia among HNC patients [15], our
study failed to detect an increased incidence of PNRT
among CCRT patients when compared with patients
undergoing RT alone, despite the increased toxicity ac-
companying CCRT.
There are two plausible explanations for this disparity.
First, patients vulnerable to pneumonia during CCRT
may be more likely to receive more comprehensive me-
dical care. For example, drug-related vomiting has been
greatly reduced through using novel antiemetics which
very well may also reduce the risk of aspiration. Second,
previous studies indicated that among patients receiving
CCRT, the incidence of post-treatment dysphagia and
stricture was considerably higher as a long-term or late
complication rather than as an early event. As the
Francis et al. study mentioned above tracked changes in
rates over seven years, and this study only had a three
month follow-up time, the Francis et al. study was far
better positioned to detect this sort of late complication.
With a trend toward expanding RT/CCRT for HNCs,
it is important to initiate a preventive strategy for all
involved practitioners when counselling patients before
RT. Particularly, a cost-investigation study showed that
morbidity and length of stay (LOS) could have signifi-
cant impact on hospital resources spent on in-patients
with cancer [23]. Since cancer patients may have higher
medication costs, it is imperative to determine who is at
risk of developing morbidities during treatment.
This retrospective study should be interpreted in light
of several limitations. First, the data analyzed in this
study was gathered from an administrative database and
lacks some important clinical and lifestyle information.
For example, we were unable to adjust for smoking
which likely had an effect on both the development of
cancer and pneumonia. Also, we were unable to incorp-
orate stage data into this analysis. Furthermore, as the
NHRI data do not provide comprehensive information
regarding the pathogen causing the pneumonia, there
was no clear delineation of the risks between cases of
PNRT from aspiration and those due to an immunocom-
promised status. Although a diagnosis of pneumonia is
objective and is usually attributable to aspiration in pa-
tients treated for HNC, some might also be vulnerable
to pneumonia due to an immunocompromised status
following aggressive therapy [11]. Based on clinical man-
ifestations or radiological patterns, it is not possible to
entirely distinguish differences between the two causes
of pneumonia.
However, we feel that the vast majority of the PNRT
subjects in this study were aspiration cases. Accordingto our previous experience [17], the incidence of aspir-
ation pneumonia during a CCRT course exceeds that of
acquired pneumonia due to the later circumstance by
about 4-fold. Furthermore, patients with an extreme
neutropenic status, such as those undergoing chemo-
therapy, are likely to have poor outcomes such as increa-
sed infections. However, given the poor immune status
of these individuals, the body is unable to effectively
mount a strong immune response despite the presence
of a foreign pathogen. This phenomenon would work
deter the clinician’s attempts at detecting the infection
and lead to an underestimation of aspiration. None-
theless, both events can lead to catastrophic effects on
treatment outcomes.
Dysphagia is a common consequence during an RT
course. No specific coding for dysphagia was identified
in the NHRI data; therefore, it was not possible to cor-
relate dysphagia with pneumonia in this study. Also, the
impact of dysphagia/dysmotility, secondary to excision
of primary tumors, could not be assessed because of the
diversities of coding numbers of the NHRI data. Thus,
further validation will be required by examining infor-
mation pertaining to postoperative swallowing function.
Conclusions
HNC patients were at particular risk of pneumonia within
90 days from the start of RT, and the estimated incidence
was approximately 5% in this period. Irrespective of the
cause of the pneumonia, old age, comorbidities, and cer-
tain tumor sites were associated with an increased risk.
Special preventive efforts should be taken during the RT
course for those at greater risk.
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